- Home
- BMRC vs BCYC Comparison
BMRC vs BCYC Comparison
Compare BMRC & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMRC | BCYC |
|---|---|---|
| Founded | 1989 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.3M | 476.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | BMRC | BCYC |
|---|---|---|
| Price | $27.16 | $7.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $28.00 | $18.73 |
| AVG Volume (30 Days) | 93.6K | ★ 240.6K |
| Earning Date | 01-26-2026 | 02-24-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $96,957,000.00 | $28,339,000.00 |
| Revenue This Year | $63.75 | N/A |
| Revenue Next Year | $16.20 | N/A |
| P/E Ratio | $44.32 | ★ N/A |
| Revenue Growth | ★ 63.31 | N/A |
| 52 Week Low | $19.14 | $6.03 |
| 52 Week High | $28.48 | $13.63 |
Technical Indicators
Market Signals| Indicator | BMRC | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 55.64 |
| Support Level | $26.30 | $6.85 |
| Resistance Level | $27.81 | $7.34 |
| Average True Range (ATR) | 0.95 | 0.32 |
| MACD | 0.11 | 0.07 |
| Stochastic Oscillator | 63.24 | 75.77 |
Price Performance
Historical ComparisonAbout BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties and others. The majority of its revenue comes from interest income.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.